Drugs / REGN5837
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05685173 | Apr 2023 → Feb 2029 expected | aggressive B-cell non-Hodgkin lymphoma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN5837 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05685173 ↗ |
| Modality | Monoclonal antibody | “REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody” NCT05685173 ↗ |
| Target | CD22 | “REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody” NCT05685173 ↗ |
| Target | CD28 | “REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody” NCT05685173 ↗ |